Isaac Bright (WG’06) has launched a new biotherapeutics business – RubrYc Therapeutics. The company just completed a $10M Series A financing led by Third Point Ventures, Paladin Capital, and Vital Venture Capital. Inspired by recent advances in molecular library synthesis and massively parallel screening and computing, RubrYc is forging a new path for information-driven discovery of therapeutic antibodies and related therapies. Using the RubrYc Interface Discovery Engine, the company can decode protein interactions through the integration of predictive analytics and biological measurements. This interface-targeted approach allows RubrYc to accelerate pre-clinical therapeutic antibody discovery, while minimizing many of the risks of industry-standard early-stage R&D.
Founded in 2017, RubrYc Therapeutics, Inc. emerged as the exclusive biotherapeutic partner of immunomics leader HealthTell. In April 2018, RubrYc Therapeutics, Inc., spun out of HealthTell to define its trailblazing role mining drug:target interfaces to build better therapies. RubrYc is supporting both proprietary discovery programs and partnered development with top-tier pharmaceutical companies.
Contact Brian at: